SAN DIEGO, March 14, 2022 – Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, today announced that company management will present at the following investor conferences:
- 32nd Annual Oppenheimer Healthcare Conference
- Tuesday, March 15th, 2022 at 1:20 pm ET
- Stifel 2022 CNS Days
- Monday, March 28th, 2022 at 8:45 AM ET
About Pipeline Therapeutics
Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address CNS and neuro-otology conditions, and its flagship program, PIPE-307, has completed a Phase 1 clinical trial in healthy volunteers to support future studies in MS patients. For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.
Company Contact:
Peter Slover
CFO
ir@pipeline-tx.com
Investor Contact:
Amy Conrad
858-914-1962
amy@juniper-point.com
